Key facts
- Corfigo’s last known valuation is $20.0M (Jan 2026).
- It has raised $5.0M across 3 recorded rounds; the latest was Seed Round ($2.4M) in Dec 2025.
- Corfigo has filed 3 Form Ds with the SEC since 2017, most recently Jul 2019 ($2.3M sold to 15 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·Watchlist + deal alerts for Corfigo
Funding rounds
3 roundsAbout Corfigo
Developer of cardiac devices designed for the ablation of atrial and ventricular tissue from an epicardial approach. The company's device is delivered and positioned adjacent to the heart for minimally invasive ablation procedures, enabling electrophysiologists to ablate diseased tissue and allow the heart to maintain a normal rhythm.
- Sector
- Healthcare
- HQ
- Montclair, NJ, United States
- Founded
- 2015
- Employees
- 3
- Website
- corfigo.com/
- Ownership
- Privately Held (backing)
Corfigo doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Corfigo shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Corfigo in its N-PORT filings yet. We sweep new filings monthly.